Stat5 is well described as a molecular regulator of lymphoid and myeloid leukemias and myeloproliferative neoplasms driven by activated tyrosine kinase signaling [36–41] and deleting Stat5 has been shown to be therapeutic for these neoplasms [42–47]. This evidence concerns the gene STAT5A and myeloproliferative disorder.